Literature DB >> 26136215

Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.

David C Broadway1, Heidi Cate.   

Abstract

Glaucoma is a leading cause of visual morbidity throughout the world and is an age-related condition, the prevalence of which rises significantly with increasing age. Glaucoma, a condition affecting the optic nerve, has a variety of subtypes with multiple aetiological factors, the most important of which are intraocular pressure (IOP) and increasing age. Treatment by lowering of IOP is the only current method, for which there is evidence, by which the rate of progressive visual deterioration can be slowed or halted. Although there are surgical and laser treatments that are efficacious in lowering IOP, the most common manner in which patients with glaucoma control their IOP is with administration of daily topical ocular hypotensive drugs (eye drops). The variety of topical drugs utilised in the management of glaucoma all have the potential to have adverse effects and/or interactions with concomitant medications, many of which may be used for other age-related conditions. Adherence with appropriate medicines has a major effect on the outcome of medical conditions and this aspect applies to the management of glaucoma. There are certain specific issues that relate to the administration of topical agents, with respect to both adverse effects and adherence. Although many suspect poor adherence in elderly patients with glaucoma, relative to younger patients, adequate evidence for this is lacking. Furthermore, the manner by which adherence issues could be improved remains inadequately understood and poorly addressed. The aims of this article were to review, from a clinical perspective, the medical therapies currently used for glaucoma and discuss adherence issues with respect to the population of patients with glaucoma, who tend to be relatively elderly.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26136215     DOI: 10.1007/s40266-015-0282-9

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  129 in total

1.  Models of open-angle glaucoma prevalence and incidence in the United States.

Authors:  H A Quigley; S Vitale
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-01       Impact factor: 4.799

2.  Natural history of normal-tension glaucoma.

Authors:  D R Anderson; S M Drance; M Schulzer
Journal:  Ophthalmology       Date:  2001-02       Impact factor: 12.079

3.  Compliance with topical timolol treatment.

Authors:  M A Kass; M Gordon; R E Morley; D W Meltzer; J J Goldberg
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

4.  Glycerol: a review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use.

Authors:  M S Frank; M C Nahata; M D Hilty
Journal:  Pharmacotherapy       Date:  1981 Sep-Oct       Impact factor: 4.705

5.  Adverse effects after glycerol orally and mannitol parenterally.

Authors:  P D'Alena; W Ferguson
Journal:  Arch Ophthalmol       Date:  1966-02

6.  The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study.

Authors:  David S Friedman; Henry D Jampel; Beatriz Muñoz; Sheila K West
Journal:  Arch Ophthalmol       Date:  2006-11

7.  An evaluation of how glaucoma patients use topical medications: a pilot study.

Authors:  Tony Tsai; Alan L Robin; Judson P Smith
Journal:  Trans Am Ophthalmol Soc       Date:  2007

8.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

9.  Incidence of acute glaucoma in Finland from 1973 to 1982.

Authors:  J Teikari; I Raivio; M Nurminen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

10.  Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study.

Authors:  Joseph Caprioli; Anne L Coleman
Journal:  Ophthalmology       Date:  2008-02-20       Impact factor: 12.079

View more
  7 in total

1.  Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma.

Authors:  Seoyoung Wy; Young Kook Kim; Jin Wook Jeoung; Ki Ho Park; Ahnul Ha
Journal:  Korean J Ophthalmol       Date:  2020-02

2.  Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study.

Authors:  Chikako Shirai; Nobushige Matsuoka; Toru Nakazawa
Journal:  BMC Ophthalmol       Date:  2021-01-21       Impact factor: 2.209

3.  Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data.

Authors:  Yunjeong Jang; Donghyun Jee; Donghwan Lee; Nam-Kyong Choi; SeungJin Bae
Journal:  Int J Environ Res Public Health       Date:  2021-04-13       Impact factor: 3.390

4.  5-(Sulfamoyl)thien-2-yl 1,3-oxazole inhibitors of carbonic anhydrase II with hydrophilic periphery.

Authors:  Stanislav Kalinin; Alexander Kovalenko; Annika Valtari; Alessio Nocentini; Maxim Gureev; Arto Urtti; Mikhail Korsakov; Claudiu T Supuran; Mikhail Krasavin
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

Review 5.  Visually driven functional MRI techniques for characterization of optic neuropathy.

Authors:  Sujeevini Sujanthan; Amir Shmuel; Janine Dale Mendola
Journal:  Front Hum Neurosci       Date:  2022-09-09       Impact factor: 3.473

Review 6.  The Role of Minimally Invasive Glaucoma Surgery Devices in the Management of Glaucoma.

Authors:  Murray Fingeret; Jaime E Dickerson
Journal:  Optom Vis Sci       Date:  2018-02       Impact factor: 1.973

7.  Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model.

Authors:  Franziska Kopp; Thomas Eickner; Stefan Polei; Karen Falke; Martin Witt; Niels Grabow; Oliver Stachs; Rudolf F Guthoff; Tobias Lindner
Journal:  Sci Rep       Date:  2017-11-17       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.